‘First in its class’ medication can help patients stay in the early stages of the disease for longer
New drug Lecanemab can slow the progress of Alzheimer’s disease. Stock image
A long-awaited treatment seen as a significant step in the fight against Alzheimer’s disease has finally been approved in Ireland, but it costs €60,000 a year.
Lecanemab promises to slow down the progress of Alzheimer’s at the early stages in suitable patients.